Table 2.

Data on overall survival, progression free survival, median treatment duration and median follow-up of the included studies.

	OS (months)			PFS (months)			Median treatment Duration (months)
Study	Experimental drug	Control	p value	Experimental drug	Control	p value	Exp	Control	Median Follow-up (months)
Yao 201110	NR	NR	0.59	11.4*	5.4*	<0.001	8.79	3.74	17
Raymond11	NR	NR	0.02	11.4	5.5	<0.001	4.6	3.7	NR
Yao 201512	NR	NR	0.04	11	3.9	<0.0001	40.4**	19.6**	21
Pavel18	NR	NR	NR	16.4	11.3	0.026	9.25	9.15	28
Yao 2015 ASCO19	NR	NR	NR	16.6*	15.4*	0.55	NR	NR	NR
Yao 200820	NR	NR	NR	16.5	14	0.34	4.5	4.5	4.5
Kulke 201521	36.7	35	0.16	16.7	14	0.12	13***	12***	25.9

OS: overall survival; PFS: progression free survival; NR: not reported.

^*according to central assessment;

^**Weeks;

^***Cycles